Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Type 2 Diabetes, Control Condition
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

In this randomized controlled trial, 30 older adults (aged\> 65 years; 15 with T2D, 15 controls) will participate in a 12-week progressive exercise training program. They will undergo pre- and post-testing that includes body composition measures; oral glucose tolerance testing; cardiovascular fitness and muscle performance testing; dietary protein efficiency assessed using the indicator amino acid oxidation (IAAO) method; and a gut microbiota trial. The dietary protein efficiency trial will include repeated ingestion of crystallized amino acids (drink) containing stable isotopes, urine samples, and breath samples. The gut microbiome trial will consist of a single ingestion of a Mediterranean-based modeled meal enriched with 13C-phenylalanine (in the drink) and repeated blood draws. Participants will also be asked to give a fecal sample after the gut microbiome trial.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: 12 week progressive exercise training — moderate - to - vigorous aerobic and strength-based exercise training will be performed 2-3 times per week for 12 weeks. Strength Training consists of a 5-minute warm-up on a stationary bike, followed by 1-3 sets on the leg press, leg extension, and leg curl machines. In addition, participants will preform upper body exercises on guided motion machines (seated chest press, shoulder press, seated rows) on alternate training days. Training intensity will gradually increase on each participants comfort level. Endurance training will be performed on a stationary bike. Exercise intensity will be controlled by heart rate and rate of perceived exertion (RPE) using the Borg's original scale (6-20 points). Weeks 1--3 will be at 50-60% of max heart rate for 30 minutes; weeks 4-6 will be at 50-60% of max heart rate for 40 minutes; weeks 7-9 will be 60-70% of max heart rate for 50 minutes; and weeks 10-12 will be at 60-70% of max heart rate for 60 minutes.

Primary Outcomes

  • Define how exercise modifies protein efficiency in T2D (From enrollment to end of 12-week intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-09
Completion: 2028-07-01
Eligibility
Age: 65 Years and older
Sex: ALL
Volunteers: true
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Illinois at Urbana-Champaign
Collaborators: American Diabetes Association
Contact Information
Study Contact:
Nicholas Burd (Professor), PhD
2172440970
naburd@illinois.edu
Gena Irwin (Research Assistant), M.S
3608883281
genai2@illinois.edu
Nicholas Burd (Professor), PhD
2172440970
naburd@illinois.edu
Freer Hall - University of Illinois
Interventions
  • Other: 12 week progressive exercise training — moderate - to - vigorous aerobic and strength-based exercise training will be performed 2-3 times per week for 12 weeks. Strength Training consists of a 5-minute warm-up on a stationary bike, followed by 1-3 sets on the leg press, leg extension, and leg curl machines. In addition, participants will preform upper body exercises on guided motion machines (seated chest press, shoulder press, seated rows) on alternate training days. Training intensity will gradually increase on each participants comfort level. Endurance training will be performed on a stationary bike. Exercise intensity will be controlled by heart rate and rate of perceived exertion (RPE) using the Borg's original scale (6-20 points). Weeks 1--3 will be at 50-60% of max heart rate for 30 minutes; weeks 4-6 will be at 50-60% of max heart rate for 40 minutes; weeks 7-9 will be 60-70% of max heart rate for 50 minutes; and weeks 10-12 will be at 60-70% of max heart rate for 60 minutes.
Study Locations (1 sites)
Freer Hall - University of Illinois, Urbana, Illinois 61801 United States
Eligibility Criteria
Inclusion Criteria: * At least 65 years old * Body mass index: 25-40 kg/m\^2 * Female: Waist to hip ratio \>0.8 * Male: Waist to hip ratio \>1.0 * Free from structured exercise during the prior 6 months (mo) weight stable for the prior 6 months T2D group: -Diagnosed by a physician with elevated glycosylated hemoglobin (HbA1c) \>6.5% Control group: -Normoglycemic with HbA1c levels not exceeding 5.6% and fasting blood glucose levels below or equal to 99 mg/dL (5.5mmol) Exclusion Criteria: * Uncontrolled diabetes (evidence of HbA1c \> 10%, prescription of insulin) * Diagnoses of diabetic neuropathy or failing diabetic neuropathy screening * Statins * Peripheral edema Consumption of ergogenic-levels of dietary supplements that may affect muscle mass (e.g., creatine, HMB), insulin-like substances, or anabolic/catabolic pro-hormones (e.g., DHEA) within 6 weeks prior to participation. * Untreated hypothyroidism, epilepsy, medications that affect vasoactivity, possibility of pregnancy, and any neurological, cardiovascular, or musculoskeletal disease that precludes exercise testing.
Conditions T2DM, CKD
Phase PHASE2
Enrollment 75
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Goal: The goal of this clinical trial is to learn if the investigational drug HTD1801 can slow the progression of kidney damage in adults diagnosed with both Type 2 Diabetes (T2DM) and Chronic Kidney Disease (CKD). Main Question it Aims to Answer: ▪ Does HTD1801 result in a greater reduction (or a smaller increase) in urine albumin-to-creatinine ratio (UACR) compared to a placebo? Researchers will compare the group receiving HTD1801 to the group receiving a placebo to see if HTD1801 is more effective in slowing kidney function decline. Participants will: * Undergo screening tests to determine eligibility. * Be randomly assigned to receive either HTD1801 capsules or matching placebo capsules twice daily for 12 weeks. * Take the study medication twice daily for 12 weeks. * Attend scheduled clinic visits (weekly for the first 4 weeks, then every 4 weeks) for assessments and check-ups. * Have their safety monitored through reporting of any health changes and routine lab tests.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: HTD1801 — 1000mg (as 4 capsules), twice a day for 12 weeks
  • Other: placebo — 4 placebo capsules, twice a day for 12 weeks.

Primary Outcomes

  • Relative change in urine albumin-to-creatinine ratio (UACR) from baseline (12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-07-09
Completion: 2027-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 75 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
Collaborators: Weifang People's Hospital, Shenzhen HighTide Biopharmaceutical Ltd.
Principal Investigators:
  • Jiandong Jiang (STUDY_DIRECTOR) - Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
  • Lulu Wang (PRINCIPAL_INVESTIGATOR) - Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
Contact Information
Study Contact:
Zhen Shen
86-10-63170236
j2025080011@pumc.edu.cn
Xingpeng Shi
86-536-8192261
shixingpeng11@163.com
Xingpeng Shi
86-536-8192261
shixingpeng11@163.com
Weifang People's Hospital
Interventions
  • Drug: HTD1801 — 1000mg (as 4 capsules), twice a day for 12 weeks
  • Other: placebo — 4 placebo capsules, twice a day for 12 weeks.
Study Locations (1 sites)
Weifang People's Hospital, Weifang, Shandong 261000 China
Eligibility Criteria
Inclusion Criteria: \- Subjects must meet all of the following criteria to be eligible for the study: 1. Male or female, aged between 18 and 75 years (inclusive) at the time of signing the informed consent form. 2. Clinically diagnosed with Type 2 Diabetes (T2DM) and Chronic Kidney Disease (CKD) before screening, evidenced by: 1. A urine albumin-to-creatinine ratio (UACR) \>200 mg/g on at least two separate occasions before screening. 2. A clinical diagnosis of CKD (KDIGO stage G1 to G3b) for at least 3 months, and an estimated glomerular filtration rate (eGFR) between 30 and 120 ml/min/1.73 m² at screening (using the CKD-EPI creatinine-cystatin C formula). 3. Confirmed diagnosis of T2DM. If on medication for T2DM, the dose must have been stable for at least 3 months before enrollment. At screening, HbA1c must be ≤9%. 4. At screening, on a stable, maximum tolerated or recommended dose of a RAAS inhibitor (e.g., valsartan, irbesartan) for at least 4 weeks. If not on a RAAS inhibitor, must be on at least one other stable, guideline-recommended kidney-protective drug (e.g., GLP-1RA, SGLT-2i, or non-steroidal MRA like finerenone) for at least 4 weeks. 5. Body Mass Index (BMI) at screening between 18.5 kg/m² and 40 kg/m². Weight must be stable (no loss \>10% in the 3 months before baseline) with no major lifestyle changes in the 3 months before screening. 6. For women of childbearing potential and sexually active men with partners of childbearing potential: agreement to use highly effective contraception or practice abstinence throughout the study and for 30 days after the last dose. 7. Able to understand, sign the informed consent form, and comply with the study protocol. Exclusion Criteria: * Exclusion Criteria Subjects who meet any of the following criteria are excluded from participation in the study. Exclusion criteria based on lab values refer to the most recent results obtained prior to randomization. Kidney Disease: 1. Congenital or hereditary kidney diseases, including polycystic kidney disease, autoimmune kidney diseases (e.g., glomerulonephritis), or congenital urinary tract malformations. 2. Currently receiving (or within the past 90 days) chronic or intermittent hemodialysis or peritoneal dialysis. Liver Disease: 3. Clinically or histologically confirmed liver cirrhosis (Fibrosis Stage 4). 4. History of hepatic decompensation (e.g., ascites, hepatic encephalopathy, or variceal bleeding). 5. Presence of the following acute or chronic liver diseases at screening: autoimmune hepatitis, primary biliary cholangitis, alcoholic liver disease, Wilson's disease, or drug-induced liver injury. Gastrointestinal Disease: 6. History of gastric bypass surgery. 7. History of peptic or gastrointestinal ulcer within 12 months prior to randomization. 8. History of clinically active inflammatory bowel disease within 12 months prior to randomization. 9. Severe gastrointestinal disease at screening that affects drug absorption, distribution, metabolism, or excretion, including chronic conditions causing recurrent diarrhea (e.g., irritable bowel syndrome, ulcerative colitis, Crohn's disease). Cardiovascular Disease: 10. History of myocardial infarction, stroke, uncontrolled arrhythmia, unstable angina, coronary artery bypass grafting, or percutaneous coronary intervention within 6 months prior to screening. 11. Current or previous history of New York Heart Association (NYHA) Class IV congestive heart failure. 12. Planned coronary, carotid, or peripheral arterial revascularization. 13. Uncontrolled hypertension despite antihypertensive therapy, defined as sustained SBP \>150 mmHg and/or DBP \>100 mmHg. Hematologic Disease: 14. Hematologic disorders or any condition causing hemolysis or red blood cell instability at screening, including but not limited to: glucose-6-phosphate dehydrogenase (G-6-PD) deficiency, hemolytic anemia, iron deficiency anemia, aplastic anemia, chronic malaria, splenectomy, reticulocytopenia. Oncology: 15. History of or current malignancy within the past 2 years, except for basal cell carcinoma or excised non-invasive squamous cell carcinoma of the skin. 16. Current, planned, or anticipated treatment with radiotherapy, cytotoxic chemotherapy, or immunomodulators (e.g., interleukins, interferons). Long-term stable use of immunosuppressants is permitted if approved by the investigator. Diagnostic Assessments: 17. Clinically significant laboratory abnormalities or ECG changes at screening, including but not limited to: 1. Platelet count \<150,000/mm³. 2. International Normalized Ratio (INR) \>1.3. 3. Alkaline Phosphatase (ALP) \>2 × Upper Limit of Normal (ULN). 4. Total bilirubin \>1.3 × ULN, unless the subject has Gilbert's syndrome. 5. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥5 × ULN. 6. Corrected QT interval (QTc) \>450 ms for males or \>470 ms for females (Fridericia's formula). 18. Active severe infection requiring parenteral antibiotic or antifungal therapy within 30 days prior to or at screening. 19. Evidence of the following viral infections at screening: 1. Human Immunodeficiency Virus (HIV) infection: defined as positive HIV antibody. 2. Syphilis infection: defined as positive Treponema pallidum antibody (TP-Ab). 3. Active Hepatitis B Virus (HBV) infection: defined as positive Hepatitis B surface antigen (HBsAg) OR positive Hepatitis B core antibody (HBcAb) with HBV-DNA \>500 IU/mL or \>2000 copies/mL. 4. Active Hepatitis C Virus (HCV) infection: defined as positive HCV antibody (HCV-Ab) with HCV-RNA above the ULN. Other: 20. Major surgery within 30 days prior to screening. 21. History of solid organ transplantation or being on a waiting list for such transplantation. 22. Blood donation or blood loss ≥400 mL within 3 months prior to screening, or anticipated need for blood transfusion within 12 weeks after randomization. 23. Known exposure to UDCA(Ursodeoxycholic Acid) or BBR(Berberine) within 3 months prior to screening, or known allergy to UDCA or BBR. 24. History or evidence of Type 1 diabetes. 25. Female subjects who are pregnant, breastfeeding, planning pregnancy, or of childbearing potential and not using highly effective contraception. 26. Participation in any clinical study of an approved or investigational product within 30 days prior to screening. 27. Any condition that, in the investigator's judgment, may jeopardize the subject's safety or compliance with the study protocol.
Conditions Preterm Premature Rupture of Membranes (...
Phase NA
Enrollment 177
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Pregnancy is a physiological process; however, it is also a dynamic period during which obstetric and medical complications that may threaten maternal and fetal health can occur. In the presence of such complications, pregnancy is defined as a high-risk pregnancy, accounting for approximately 10-20% of all pregnancies. Due to the increased risk of maternal and fetal morbidity and mortality, high-risk pregnancies are considered a significant public health issue. Among high-risk pregnancies, premature rupture of membranes (PROM) and particularly preterm premature rupture of membranes (PPROM) are obstetric conditions associated with serious risks for maternal and perinatal outcomes. PPROM is responsible for a substantial proportion of preterm births and is associated with an increased risk of neonatal complications. During the course of PROM and PPROM, the latency period between membrane rupture and delivery constitutes a significant source of uncertainty and psychosocial burden for pregnant women. Factors such as prolonged hospitalization, risk of complications, and fear of fetal loss may lead to increased levels of stress, anxiety, and depression in this population. In the face of intense stress and uncertainty, coping strategies emerge as an important determinant of psychological outcomes. Coping refers to the cognitive and behavioral efforts individuals employ to manage situations perceived as threatening and is generally classified into active and avoidant coping strategies. Avoidant coping strategies have been associated with higher levels of anxiety and depression, whereas adaptive coping strategies are reported to enhance psychological resilience. Maternal psychological status may influence not only the mother's mental health but also fetal well-being. In this context, the non-stress test (NST) is an important tool for evaluating fetal autonomic nervous system function and allows monitoring of the relationship between maternal psychological status and fetal physiological responses. However, findings regarding the relationship between maternal anxiety and depression and NST parameters remain inconsistent. Current clinical management of PROM and PPROM primarily focuses on preventing obstetric complications, while the maternal psychological dimension often remains secondary. Therefore, safe and feasible non-pharmacological interventions during pregnancy have gained increasing attention. Emotional Freedom Technique (EFT) and music therapy are among the non-pharmacological interventions shown to be effective in reducing stress, anxiety, and depression during pregnancy. However, no studies have been identified in the literature evaluating the effects of these interventions on maternal psychological status, coping strategies, and fetal well-being in high-risk pregnancy groups such as PROM and PPROM. Therefore, randomized controlled trials are needed to evaluate the effects of EFT and music therapy on maternal psychological status, coping…

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Emotional Freedom Technique (EFT) — Before the intervention, participants will receive standardized training on the EFT procedure using written and visual materials. The intervention is planned in two sessions. Following the pre-test assessments, the first 30-minute EFT session will be conducted by the researcher. After the first session, participants will be instructed to continue practicing EFT on their own every evening (preferably before bedtime) for seven days, and this process will be monitored daily by the researcher. At the end of one week, the second 30-minute EFT session will be administered by the researcher.
  • Behavioral: Music Therapy — Before the intervention, participants will receive standardized training on the music therapy procedure using written and visual materials. The intervention is planned in two sessions. Following the pre-test assessments, the first 30-minute music therapy session will be conducted by the researcher. After the first session, participants will be instructed to listen to the same music track every evening (preferably before bedtime) for seven days, and this process will be monitored daily by the researcher. At the end of one week, the second 30-minute music therapy session will be administered by the researcher.

Primary Outcomes

  • Depression Anxiety Stress Scale-21 (DASS-21) (Baseline and immediately after completion of the second (final) intervention session following a 1-week self-practice period)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-01
Completion: 2027-03
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 177 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Selcuk University
Contact Information
Study Contact:
Süreyya Kılıç, PhD(c)
+90 501 578 99 08
sureyyakilic117@gmail.com
Interventions
  • Behavioral: Emotional Freedom Technique (EFT) — Before the intervention, participants will receive standardized training on the EFT procedure using written and visual materials. The intervention is planned in two sessions. Following the pre-test assessments, the first 30-minute EFT session will be conducted by the researcher. After the first session, participants will be instructed to continue practicing EFT on their own every evening (preferably before bedtime) for seven days, and this process will be monitored daily by the researcher. At the end of one week, the second 30-minute EFT session will be administered by the researcher.
  • Behavioral: Music Therapy — Before the intervention, participants will receive standardized training on the music therapy procedure using written and visual materials. The intervention is planned in two sessions. Following the pre-test assessments, the first 30-minute music therapy session will be conducted by the researcher. After the first session, participants will be instructed to listen to the same music track every evening (preferably before bedtime) for seven days, and this process will be monitored daily by the researcher. At the end of one week, the second 30-minute music therapy session will be administered by the researcher.
Study Locations (1 sites)
Konya City Hospital, Konya, Konya 42020 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Women aged 18 years and older * Able to speak and understand Turkish * Diagnosed with preterm premature rupture of membranes (PPROM) * Gestational age between 28+0 and 35+5 weeks * Score of ≥1 on the Subjective Units of Disturbance Scale (SUDS) * Singleton pregnancy * Able and willing to communicate and participate in the study Exclusion Criteria: * Pregnancy achieved via assisted reproductive technologies * Presence of any obstetric complication other than PPROM * Presence of major fetal anomalies * Active labor at the time of recruitment * Hearing impairment * Presence of infection, wounds, or scars at tapping sites (for EFT application) * History of severe psychiatric disorder or currently receiving psychiatric treatment * Any maternal or fetal condition requiring emergency medical intervention
Conditions Diabetes Mellitus (Type 1 and Type 2)
Phase Not Applicable
Enrollment 400
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to examine the relationships between socio-ecological determinants, health literacy, and self-management agency among patients with diabetes mellitus. Using a path analysis framework, the study investigates how multi-level socio-ecological factors and different dimensions of health literacy influence patients' capacity for diabetes self-management. Understanding these pathways will support the development of comprehensive, context-sensitive interventions to improve diabetes outcomes.

Design

Study type: Observational Observational model: Other Time perspective: Cross Sectional

Interventions / Regimen

  • Other: Questionnaire-based assessment — No clinical or behavioral intervention is applied. This observational study involves a questionnaire-based assessment to collect data on socio-ecological determinants, health literacy, and self-management agency among adult patients with diabetes mellitus.

Primary Outcomes

  • Self-management agency (Baseline (cross-sectional assessment))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-05-15
Completion: 2026-07-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Alexandria University
Principal Investigators:
  • Mohamed Fakhry Ahmed Salem (PRINCIPAL_INVESTIGATOR) - Alexandria University
Contact Information
Study Contact:
Mohamed Fakhry Ahmed Salem, phd
+201286038014
Mohamed.Fakhry@alexu.edu.eg
Ahmed Salem
Mohamed.Fakhry@alexu.edu.eg
Mohamed Fakhry Ahmed Salem, PhD Medical-Surgical Nursing
01286038014
Mohamed.Fakhry@alexu.edu.eg
Alexandria University Hospital, Faculty of Nursing
Interventions
  • Other: Questionnaire-based assessment — No clinical or behavioral intervention is applied. This observational study involves a questionnaire-based assessment to collect data on socio-ecological determinants, health literacy, and self-management agency among adult patients with diabetes mellitus.
Study Locations (2 sites)
Alexandria University Hospital, Faculty of Nursing, Alexandria, Alexandria Governorate 21511 Egypt
Faculty of Nursing, Alexandria University, Alexandria, Alexandria Governorate 21511 Egypt
Eligibility Criteria
Inclusion Criteria: * \- Adults aged 18 years and older. * Diagnosed with type 1 or type 2 diabetes mellitus. * Receiving follow-up care in outpatient or primary healthcare settings. * Able to communicate verbally and provide informed consent. Exclusion Criteria: * \- Patients with severe cognitive impairment. * Patients with acute medical conditions preventing participation. * Pregnant women diagnosed with gestational diabetes.

Rocklatan vs Latanoprost Post-DSLT

NCT07465913
Recruiting
Conditions Glaucoma
Phase PHASE4
Enrollment 36
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a randomized, double-masked, single-site, prospective, contralateral eye study designed to evaluate the outcomes of Direct Selective Laser Trabeculoplasty (DSLT) followed by the addition of combination netarsudil and latanoprost (Rocklatan) versus latanoprost monotherapy. The study will be conducted at one investigational site. The primary endpoint is the change in mean diurnal intraocular pressure (IOP) from baseline (post DSLT and post washout) at visit 3 between the two groups. Secondary endpoints include the change in mean IOP from baseline at each timepoint (8am, 12pm, 4pm) at visit 3 between groups, and the mean percentage decrease in IOP from baseline for each group. Assessments will be conducted at three key visits: Visit 1 (Screening Phase and DSLT Procedure on Day 0), Visit 2 (Baseline Visit post washout at Week 8), and Visit 3 (Follow-Up Visit 1 at Week 12). Each visit will include specific examinations and measurements such as visual field and OCT imaging, diurnal IOP measurements, and documentation of adverse events.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: Triple

Interventions / Regimen

  • Drug: Rocklatan 0.02%-0.005% Ophthalmic Solution — netarsudil and latanoprost 0.02%/0.005%
  • Drug: Latanoprost 0.005% Ophthalmic Solution — Latanoprost 0.005%

Primary Outcomes

  • Change in mean diurnal intraocular pressure (IOP) from baseline (3 months post-treatment initiation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2026-05-14
Completion: 2027-05-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 36 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Eye Centers of Southeast Texas
Collaborators: Sengi
Principal Investigators:
  • Kevin Talbot, MD (PRINCIPAL_INVESTIGATOR) - Eye Centers of Southeast Texas
Contact Information
Study Contact:
Carol McKee
409-833-0444
cmckee@eyecentersbmt.com
Eye Centers of Southeast Texas
Kevin Talbot, MD
Eye Centers of Southeast Texas
Interventions
  • Drug: Rocklatan 0.02%-0.005% Ophthalmic Solution — netarsudil and latanoprost 0.02%/0.005%
  • Drug: Latanoprost 0.005% Ophthalmic Solution — Latanoprost 0.005%
Study Locations (1 sites)
Eye Centers of Southeast Texas, Beaumont, Texas 77707 United States
Eligibility Criteria
Inclusion Criteria: * Adults (≥18 years) with a diagnosis of mild to moderate bilateral primary open-angle glaucoma (POAG) or open-angle glaucoma (OAG). * On 3 topical glaucoma medications at screening, one of which must be a prostaglandin analog. * Post-DSLT and post-washout, baseline intraocular pressure (IOP) 16-36 mmHg in both eyes. * Best-corrected visual acuity (BCVA) ≥20/60 in both eyes. * Ability and willingness to provide informed consent. Exclusion Criteria: * Ocular hypertension only (no glaucomatous damage). * Inability or medical ineligibility for washout of ocular hypotensive medications. * Prior selective laser trabeculoplasty (SLT) within 12 months of screening. * History of glaucoma surgery (trabeculectomy, tube shunt, minimally invasive glaucoma surgery \[MIGS\] affecting outflow). * Narrow or closed angles with gonioscopy (Shaffer grading ≤2). * Active ocular infection, uveitis, or severe dry eye. * Corneal pathology interfering with IOP measurement. * Advanced glaucoma (threat to fixation). * Known hypersensitivity to Rocklatan, latanoprost, or study medication components. * Pregnancy or lactation.
Conditions Breast Cancer, Early Stage, Hormone Rece...
Phase NA
Enrollment 264
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Breast-conserving surgery has been widely used in clinical practice, but surgical incisions still impact postoperative patient satisfaction with breast appearance. The development of tumor ablation technologies has introduced new possibilities for breast cancer surgical treatment. The hybrid cryo-thermal ablation system, an advanced minimally invasive tumor treatment device independently developed in China, employs a combined approach of deep cryoablation and high-intensity heating for therapy and has been approved for treating solid tumors, including breast cancer. This study is a prospective, single-center, randomized controlled trial. Eligible patients with newly diagnosed early-stage breast cancer treated at the Breast Center of Peking University People's Hospital will be enrolled and randomized in a 1:1 ratio to receive either hybrid cryo-thermal ablation (experimental group) or breast-conserving surgery (control group). Data collected will include: Baseline clinicopathological characteristics, Surgical details (operation time, intraoperative/postoperative complications, etc.), Peripheral blood lymphocyte distribution, Treatment efficacy (ipsilateral breast tumor recurrence rate, disease-free survival, overall survival), Aesthetic outcomes (BREAST-Q score). Primary endpoint: Ipsilateral breast local recurrence rate, Secondary endpoints: Safety (incidence of adverse events assessed by CTCAE criteria), Disease-free survival and overall survival, Quality of life assessment (breast satisfaction), Exploratory endpoints: Pathological response of ablated tumor tissue, Correlation analysis between postoperative imaging (MRI/ultrasound) features and recurrence risk.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: breast conserving surgery — According to the 《Chinese Breast Cancer Diagnosis and Treatment Guidelines》, standard breast-conserving surgery (BCS) was performed, with pathologically confirmed negative margins.
  • Procedure: cryo-thermal ablation — Real-time ultrasound imaging to confirm tumor size and shape. Mark the ablation target zone, including the 5-mm peripheral margin. Ablation Procedure Step 1: Probe Insertion Under ultrasound guidance, insert the cryo-thermal ablation probe into the tumor center. Step 2: Dual-Cycle Ablation (Freeze-Heating-Freeze) First Freeze Cycle: Duration: 10-15 minutes. Temperature: Rapid cooling to -196°C (liquid nitrogen). Endpoint: Ice ball fully envelops the tumor + 5-mm margin (confirmed by ultrasound). Heating Phase: Temperature: Rapid heating to 80°C. Duration: 5-10 minutes (thawing and thermal damage enhancement). Second Freeze Cycle: Repeat freezing to ensure complete tumor destruction.

Primary Outcomes

  • Ipsilateral Breast Tumor Recurrence Rate (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-01
Completion: 2031-12-31
Eligibility
Age: 50 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 264 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking University People's Hospital
Principal Investigators:
  • shu wang, doctor (STUDY_DIRECTOR) - Peking University People's Hospital
Contact Information
Study Contact:
yuan peng, doctor
86+13671287670
13671287670@163.com
yuan peng, Dr
Peking University People's Hospital
Interventions
  • Procedure: breast conserving surgery — According to the 《Chinese Breast Cancer Diagnosis and Treatment Guidelines》, standard breast-conserving surgery (BCS) was performed, with pathologically confirmed negative margins.
  • Procedure: cryo-thermal ablation — Real-time ultrasound imaging to confirm tumor size and shape. Mark the ablation target zone, including the 5-mm peripheral margin. Ablation Procedure Step 1: Probe Insertion Under ultrasound guidance, insert the cryo-thermal ablation probe into the tumor center. Step 2: Dual-Cycle Ablation (Freeze-Heating-Freeze) First Freeze Cycle: Duration: 10-15 minutes. Temperature: Rapid cooling to -196°C (liquid nitrogen). Endpoint: Ice ball fully envelops the tumor + 5-mm margin (confirmed by ultrasound). Heating Phase: Temperature: Rapid heating to 80°C. Duration: 5-10 minutes (thawing and thermal damage enhancement). Second Freeze Cycle: Repeat freezing to ensure complete tumor destruction.
Study Locations (1 sites)
Peking University People's Hospital, Beijing, Beijing Municipality 100044 China
Eligibility Criteria
Inclusion Criteria: * 1.Age ≥50 Years 2.Unifocal disease (single tumor) confirmed by ultrasound, MRI, or mammography. Ultrasound visibility: Essential for precise intraoperative ablation targeting. 3.Pathologically Confirmed Invasive Ductal Carcinoma (IDC)。Diagnostic Method: Core needle biopsy (CNB) confirming IDC. 4.Histologic Grade: G1 or G2; ER/PR-positive and HER2-negative. 5.TNM stage: IA. Tumor Size: ≤2 cm; Lymph Node Status: Clinically \& radiologically negative (no palpable/imaging-detected axillary involvement). 6.Written consent for clinical trial participation and acceptance of random assignment Exclusion Criteria: * 1.Extensive intraductal component (EIC) suggested by imaging or pathology. 2.Invasion of adjacent skin or muscle. 3.Prior anticancer treatment for the current disease, including but not limited to chemotherapy, endocrine therapy, targeted therapy, or immunotherapy. 5.Refusal to undergo breast-conserving surgery. 6.Pregnancy or lactation. 7.Previous radiotherapy to the affected breast or other contraindications to radiotherapy. 8.Concurrent untreated malignancies or severe systemic diseases, 9.Known allergy, intolerance, or contraindications to cryotherapy (e.g., cryoglobulinemia, implanted electronic devices). 10.Inability to comply with follow-up or refusal of adjuvant therapy. 11.Vulnerable populations, including individuals with neurological disorders, cognitive impairment, or critical illness.
Conditions Late-Life Depression
Phase NA
Enrollment 84
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this clinical trial is to investigate the effects of L-serine supplementation on cognitive decline and psychosocial functioning in older adults with late-life depression (LLD). The study will evaluate changes in depressive symptoms, neural and cognitive functioning, and will assess neurophysiological, metagenomic, and biochemical alterations associated with L-serine supplementation compared with placebo. The main research questions are: * Does L-serine supplementation affect cognitive function, depressive symptoms, and neural functioning in individuals with late-life depression? * What biological mechanisms may underlie the effects of L-serine on cognitive decline? Participants will be randomly assigned to one of two study arms: an intervention group (total n = 42) receiving L-serine at a dose of 6 g/day for 48 weeks, and a placebo group (total n = 42) receiving 6 g/day of maltodextrin for the same duration. All participants will be assessed at three time points: T0 (baseline, prior to trial initiation), T18 (after 18 weeks), and T48 (after 48 weeks, at the end of the trial). At each assessment, participants will: * complete clinical questionnaires and a neuropsychological assessment; * provide blood, fecal, and urine samples; * undergo electroencephalographic (EEG) recordings.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Double

Interventions / Regimen

  • Dietary Supplement: L-serine supplementation — Participants randomized to the experimental arm will receive L-serine supplementation (6 g/day), administered orally as a single stick per day for a total duration of 48 weeks.
  • Other: Placebo — Participants randomized to the Placebo arm will receive Maltodextrine supplementation (6 g/day), administered orally as a single stick per day for a total duration of 48 weeks.

Primary Outcomes

  • Geriatric Depression Scale - 15 (Baseline; week 18; week 48 (end of the trial))
  • Repeatable Battery for the Assessment of Neuropsychological Status (Baseline, Week 18; Week 48 (end of the trial))
  • Patient Health Questionnaire - 9 (Baseline; Week 18; Week 48 (end of the trial))
  • Montgomery-Åsberg Depression Rating Scale (Baseline, Week 18; Week 48 (end of the trial))
  • World Health Organization Quality of Life - Bref (Baseline, Week 18, Week 48 (end of trial))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-01
Completion: 2029-02-01
Eligibility
Age: 65 Years and older
Sex: ALL
Volunteers: false
Enrollment: 84 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: IRCCS Centro San Giovanni di Dio Fatebenefratelli
Contact Information
Study Contact:
Moira Marizzoni, PhD
(+39) 030 35 01 563
mmarizzoni@fatebenefratelli.eu
Annamaria Cattaneo, PhD
0303501598
acattaneo@fatebenefratelli.eu
IRCCS Centro San Giovanni di Dio Fatebenefratelli
Interventions
  • Dietary Supplement: L-serine supplementation — Participants randomized to the experimental arm will receive L-serine supplementation (6 g/day), administered orally as a single stick per day for a total duration of 48 weeks.
  • Other: Placebo — Participants randomized to the Placebo arm will receive Maltodextrine supplementation (6 g/day), administered orally as a single stick per day for a total duration of 48 weeks.
Study Locations (1 sites)
IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, 25125 Italy
Eligibility Criteria
Inclusion Criteria: * Age 65-85 years; * Presence of depressive symptoms, defined as a score ≥ 5 on the Geriatric Depression Scale-15 items (GDS-15) or ≥ 5 on the Patient Health Questionnaire-9 (PHQ-9). Exclusion Criteria: * Diagnosis of dementia; * Use of antibiotics or anti-inflammatory medications within the previous 8 weeks; * Active gastrointestinal disease; * Severe chronic medical conditions (e.g., advanced-stage cancer, severe cardiac or renal disorders, or other debilitating diseases); * Renal dysfunction; * Current alcohol or substance abuse; * Major surgical procedures within the previous 6 months.
Conditions Diabetes Mellitus, Type 2, Diabetes Mell...
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to evaluate whether an audio diary mobile application (Fabla-diabetesMM) is feasible to use and may support self-management in older adults with type 1 or 2 diabetes and multimorbidity. The main questions it aims to answer are: * Is it feasible to adapt and implement the Fabla-diabetesMM audio diary mobile app among 30 older adults with diabetes and multimorbidity * Does the use of the audio diary mobile app affect self-management outcomes

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: Fabla Mobile App — Participants will use an adapted audio diary mobile application (Fabla-diabetesMM) designed to collect daily structured and semi-structured audio reflections on health conditions, symptoms, self-management strategies, goal attainment, and feasibility feedback. The app is tailored for older adults, including adjustments to interface, font, navigation, and question wording. Intervention Components: * Daily audio diary entries for 7 days, with optional continued use up to 1 or 3 months * Structured survey items integrated into the app (e.g., symptoms, self-regulation, self-efficacy, healthcare use) * Semi-structured audio prompts about daily experiences, self-management, and health changes * Reminder notifications to encourage diary completion * Video instructions on how to use the app

Primary Outcomes

  • Feasibility of the Audio Diary Mobile App (Day 1-7; Day 7-1 or 3 months)
  • Expressiveness (Day 1-7; Day 7-1 or 3 months)
  • Acceptability, Appropriateness, and Feasibility Measures (Day 1-7; Day 7-1 or 3 months)
  • System Usability Scale (Day 1-7; Day 7-1 or 3 months)
  • Rates of interest (Screening)
  • Rates of eligibility (Screening)
  • Rates of completion (Day 1; Day 1-7; Day 7; Day 7-1 or 3 months; 1 month; 3 months)
  • Linguistic Inquiry and Word Count (LIWC) analysis of the audio diaries (Day 1-7; Day 7-1 or 3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-09
Completion: 2027-03
Eligibility
Age: 65 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Emory University
Principal Investigators:
  • Wenhui Zhang, PhD (PRINCIPAL_INVESTIGATOR) - Emory University
Contact Information
Study Contact:
Wenhui Zhang, PhD
762-499-0411
wenhui.zhang@emory.edu
Wenhui Zhang, PhD
762-499-0411
wenhui.zhang@emory.edu
Emory Healthcare
Interventions
  • Other: Fabla Mobile App — Participants will use an adapted audio diary mobile application (Fabla-diabetesMM) designed to collect daily structured and semi-structured audio reflections on health conditions, symptoms, self-management strategies, goal attainment, and feasibility feedback. The app is tailored for older adults, including adjustments to interface, font, navigation, and question wording. Intervention Components: * Daily audio diary entries for 7 days, with optional continued use up to 1 or 3 months * Structured survey items integrated into the app (e.g., symptoms, self-regulation, self-efficacy, healthcare use) * Semi-structured audio prompts about daily experiences, self-management, and health changes * Reminder notifications to encourage diary completion * Video instructions on how to use the app
Study Locations (1 sites)
Emory Healthcare, Atlanta, Georgia 30329 United States
Eligibility Criteria
Inclusion Criteria: * Diagnosed type 1 or 2 diabetes and at least one comorbidity (eg, obesity, HIV, heart failure, polycystic ovary syndrome, obstructive sleep apnea, and prediabetes with and without hypertension) * Being able to fill in the Redcap surveys, and install and use the audio diary app. Exclusion Criteria: •Those who cannot use (e.g., no mobile phone, incompatible system), read, type, speak, or understand English in Redcap or the audio diary mobile app.
Conditions Breast Cancer, Health, Subjective, Obesi...
Phase Not Applicable
Enrollment 60
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The main objective of this project is to determine the possible association between the levels of certain bioactive lipids, which the body produces from dietary fatty acids, and tumor characteristics in breast cancer patients, as well as their relationship with overweight/obesity. Specific objectives are: * To analyse anthropometric and body composition changes. * To evaluate physical activity level. * To determine dietary profile. * To determine the adherence to Mediterranean dietary pattern. * To assess the quality of life. * To determine levels of specialized pro-resolving lipid mediators The target sample size is 60 subjects. Participants will be allocated in four groups: * Group 1: Postmenopausal healthy women with overweight/obesity (n=15) * Group 2: Postmenopausal healthy women with normoweight (n=15) * Group 3: Postmenopausal women with breast cancer and overweight/obesity (n=15) * Group 4: Postmenopausal women with breast cancer and normoweight (n=15)

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Other: Observational study (baseline) — Data will be collected at a single time point.
  • Other: Observational study (baseline and 1 year) — Data will be collected at two time points during the study period.

Primary Outcomes

  • Lipid mediators profile (Clinical Investigation Day 1 and Clinical Investigation Day 3)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-10-15
Completion: 2027-12-30
Eligibility
Age: Not reported
Sex: FEMALE
Volunteers: true
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Clinica Universidad de Navarra, Universidad de Navarra
Principal Investigators:
  • Miguel Burgos, PhD (PRINCIPAL_INVESTIGATOR) - Center for Nutrition Research
  • María Jesús Moreno-Aliaga, PhD (PRINCIPAL_INVESTIGATOR) - Center for Nutrition Research
  • María Soledad García-Unciti, PhD (STUDY_CHAIR) - Center for Nutrition Research
Contact Information
Study Contact:
Miguel Burgos, PhD
+34948425600
mburgosloz@unav.es
María Jesús Moreno-Aliaga, PhD
+34948425600
mjmoreno@unav.es
Miguel Burgos, PhD
+34948425600
mburgosloz@unav.es
Center for Nutrition Research
Interventions
  • Other: Observational study (baseline) — Data will be collected at a single time point.
  • Other: Observational study (baseline and 1 year) — Data will be collected at two time points during the study period.
Study Locations (2 sites)
Center for Nutrition Research, Pamplona, Navarre 31008 Spain
Clínica Universidad de Navarra, Pamplona, Navarre 31008 Spain
Eligibility Criteria
HEALTHY PARTICIPANTS: Inclusion Criteria: * Postmenopause (al least 1 year). * Normoweight or overweight/obesity. * No personal history of cancer. * Stable weight over the last 3 months (±5%). * Willing to sign the informed consent and comply with all study procedures. Exclusion Criteria: * Personal history of cancer. * Current weight loss treatment (diet, supplementation, surgery, others...). * Bariatric surgery. * No stable pharmacological treatment for at least 3 months. * Diabetes treatment and hormone replacement therapy. * Relevant functional or structural abnormalities of the gastrointestinal tract, such as malformations, angiodysplasias, active peptic ulcers, chronic inflammatory or malabsorption diseases, hiatal hernia, chronic reflux, etc. * High alcohol intake, more than 14 units per week for women and 20 units per week for men. * Surgical interventions resulting in permanent sequelae of the gastrointestinal tract. * Liver disease, except for non-alcoholic fatty liver disease. * Cognitive and/or psychiatric impairment. * Poor compliance or difficulty following study procedures. BREAST CANCER PARTICIPANTS: Inclusion Criteria: * Postmenopause (at least 1 year). * Normoweight or overweight/obesity. * Luminal subtype breast cancer, stages I-II, who require tumor resection and do not require preoperative treatment. * Willing to sign the informed consent and comply with all study procedures. Exclusion Criteria: * Luminal subtype breast cancer stages over than II or other type of breast cancer. * Require preoperative treatment.
Conditions Margin Assessment, Breast Cancer
Phase Not Applicable
Enrollment 100
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This analytical performance study aims to validate the SPCTRone system for use in breast conserving surgery of breast cancer patients. By collecting spectral biomarkers and correlating these with the golden standard of histopathological assessment by a pathologist, we aim to train and optimize an AI model that is able to achieve the following outcomes with classifying tissues: * Sensitivity (percentage of classified positive margins of actual positive margins): ≥ 96% CI 95.5-97.5% * Specificity (percentage of classified free margins of actual free margins): 96% CI 95.5-97.5% * Accuracy (total correctly classified margins): ≥ 96% CI 95.5-97.5% * Negative predictive value (amount of true negative - free margins - among the classified negative margins): ≥ 95% CI 94.5-96.5%

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Diagnostic performance of SPCTRone system to assess margin status of breast cancer specimens (Through study completion, an average of 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-01-12
Completion: 2026-08-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: SPCTR
Collaborators: UMC Utrecht, Martini Hospital Groningen
Contact Information
Study Contact:
Robin Merjenburgh
+31681119503
robin@spctr.tech
Wendy Kelder, Dr
Martini Ziekenhuis
Arjen Witkamp, Dr.
UMC Utrecht
Interventions
N/A
Study Locations (2 sites)
Martini Ziekenhuis, Groningen, Provincie Groningen 9728NT Netherlands
UMC Utrecht, Utrecht, Utrecht 3584CX Netherlands
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Confirmed diagnosis breast cancer for which surgical procedure is needed * Planned for breast conserving surgery Exclusion Criteria: * Person that undergoes breast amputation without confirmed cancer diagnosis
Conditions Opioid-Induced Respiratory Depression, P...
Phase Not Applicable
Enrollment 300
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will evaluate whether quantitative pupillometry measurements can be used to identify children at risk for postoperative opioid-induced respiratory depression (OIRD) following tonsillectomy. Opioid-induced respiratory depression is a serious and potentially life-threatening complication that can occur after surgery, and current monitoring approaches are limited in their ability to predict which patients are at highest risk. In this prospective observational cohort study, approximately 300 pediatric patients undergoing tonsillectomy will undergo non-invasive pupillometry measurements at defined perioperative time points, including preoperative, intraoperative, and postoperative periods. Pupillometry measurements will be collected using a commercially available, FDA-regulated infrared pupillometer. These measurements will include pupil size, constriction and dilation velocities, and latency in response to light stimulation. Pupillometry data will be collected for research purposes only and will not be used to guide clinical care or treatment decisions. Standard clinical care will not be altered as part of this study. Clinical outcomes, including the occurrence of postoperative opioid-induced respiratory depression, opioid use, sedation levels, pain scores, and other postoperative events, will be recorded from the medical record. The goal of this study is to evaluate the relationship between pupillary response patterns and the occurrence of postoperative respiratory depression, and to support the development of predictive models that may improve early identification of patients at risk for opioid-related adverse events.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Device: Infrared Pupillometry — Non-invasive pupillometry measurements will be performed using a commercially available, FDA-regulated infrared pupillometer. Measurements will be collected at predefined perioperative time points for research purposes only and will not be used to guide clinical care.

Primary Outcomes

  • Occurrence of Postoperative Opioid-Induced Respiratory Depression (From arrival in post-anesthesia care unit (PACU) through PACU discharge (up to 4 hours postoperatively))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-05-04
Completion: 2027-04-30
Eligibility
Age: 3 Years and older
Sex: ALL
Volunteers: true
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: NeurOptics Inc
Collaborators: National Institute on Drug Abuse (NIDA), University of Pittsburgh Medical Center, University of California, San Francisco
Principal Investigators:
  • Jeffrey W Oliver, PhD (STUDY_DIRECTOR) - NeurOptics Inc
Contact Information
Study Contact:
Alisha Maslanka, BS, CCRC
412-491-2748
alisha.maslanka@chp.edu
Senthilkumar Sadhasivam, MD
513-253-4684
sadhasivams@upmc.edu
Rachel Eshima McKay, MD
415-310-7722
Rachel.Eshima@ucsf.edu
UCSF Benioff Children's Hospital
Interventions
  • Device: Infrared Pupillometry — Non-invasive pupillometry measurements will be performed using a commercially available, FDA-regulated infrared pupillometer. Measurements will be collected at predefined perioperative time points for research purposes only and will not be used to guide clinical care.
Study Locations (2 sites)
UCSF Benioff Children's Hospital, San Francisco, California 94158 United States
UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania 15213 United States
Eligibility Criteria
Inclusion Criteria: * Age 3 to less than 18 years * Scheduled to undergo tonsillectomy with or without adenoidectomy * Planned postoperative recovery in a monitored clinical setting (e.g., post-anesthesia care unit) * Ability to obtain informed consent from parent or legal guardian and assent from the participant when developmentally appropriate Exclusion Criteria: * Known neurologic or ophthalmologic conditions that may affect pupillary function * Use of medications known to significantly alter pupillary response outside of standard perioperative care * Inability to obtain adequate pupillometry measurements (e.g., due to eye injury or inability to safely perform measurement) * Patients not receiving opioids as part of perioperative care * Any condition that, in the opinion of the investigator, would interfere with study participation or data interpretation
Conditions Anatomic Stage I Breast Cancer AJCC v8, ...
Phase NA
Enrollment 120
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This clinical trial studies whether a healthy living intervention (HLI), with or without a physical activity intervention (PAI), helps maintain the ability to exercise, heart health, and quality of life in breast cancer patients who are scheduled to receive chemotherapy treatment. Early detection and enhanced therapies for breast cancer have improved 5-year cancer-related survival rates. Unfortunately, many breast cancer survivors are at high risk for long-term exercise intolerance, decreased heart health, and lower quality of life following chemotherapy. Currently, there are no effective therapies to help patients maintain these areas throughout chemotherapy. The HLI in this study includes virtual health education classes, which provide useful information on topics like proper nutrition, managing stress, and sleep practices. This may help patients understand the importance of living a healthy lifestyle during chemotherapy. The PAI in this study consists of virtual exercise sessions personalized to the needs of the patient, which may make it easier for patients to stay active during chemotherapy. HLI with PAI may be a more effective way to help maintain ability to exercise, heart health, and quality of life in breast cancer patients who are scheduled to receive chemotherapy treatment.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Other: Exercise Intervention — Attend virtual personalized exercise sessions
  • Other: Educational Intervention — Attend organized health workshops
  • Other: Supportive Care — Receive Fitbit device, resistance bands, and/or loaner tablet
  • Procedure: Biospecimen Collection — Undergo blood sample collection
  • Procedure: Magnetic Resonance Imaging — Undergo CMR
  • Procedure: Magnetic Resonance Imaging — Undergo ExeCMR
  • Other: Questionnaire Administration — Ancillary studies
  • Procedure: Accelerometry — Ancillary Studies

Primary Outcomes

  • Peak oxygen consumption (VO2) (At baseline and 24 weeks)
  • Left ventricular ejection fraction (LVEF) (At baseline and 24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-05-27
Completion: 2030-04-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Wake Forest University Health Sciences
Principal Investigators:
  • Glenn Lesser, MD (STUDY_CHAIR) - Wake Forest University Health Sciences
Contact Information
Study Contact:
Karen Craver, MT, MHA
336-716-0891
NCORP@wfusm.edu
Glenn Lesser, MD
336-716-0891
ncorp@wfusm.edu
Wake Forest NCORP RB
Karen Craver, MHA
336-716-0891
ncorp@wfusm.edu
Wake Forest NCORP RB
Interventions
  • Other: Exercise Intervention — Attend virtual personalized exercise sessions
  • Other: Educational Intervention — Attend organized health workshops
  • Other: Supportive Care — Receive Fitbit device, resistance bands, and/or loaner tablet
  • Procedure: Biospecimen Collection — Undergo blood sample collection
  • Procedure: Magnetic Resonance Imaging — Undergo CMR
Study Locations (2 sites)
Wake Forest NCORP RB, Winston-Salem, North Carolina 27157 United States
Wake Forest NCORP Research Base, Winston-Salem, North Carolina 27157 United States
Eligibility Criteria
Inclusion Criteria: * Stage I-III breast cancer (including inflammatory and newly diagnosed, or locally recurrent \[if prior treatment received ≥ 2 years prior\] but not metastatic breast cancer being treated with curative intent). All molecular subtypes (estrogen receptor \[ER\], progesterone receptor \[PR\], human epidermal growth factor receptor 2 \[HER2\], etc.) are acceptable * Scheduled to receive neoadjuvant or adjuvant cytotoxic chemotherapy. Patient must be enrolled ≤ 3 weeks from start of cytotoxic chemotherapy * Age 18 to 85 years at enrollment. The upper age cut-off is due to the increased risk of injury in the older population during the CPET, which uses stationary bicycle exercise testing, outweighing the benefit of including this age group * Must be able to complete a stationary bicycle exercise test where you pedal against some resistance on a stationary bike with supervisors at your side per patient self-report * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * Able to walk at least 2 blocks without chest pain, dyspnea, shortness of breath or fainting per patient self-report * Able to hold breath for 8 seconds * Must be able to read and understand English language * Must have access to a device that allows teleconferencing (e.g., Zoom calls) or be willing to participate in the Tablet Lending Program * Must be willing to download and use the Trainerize application to their personal device or be willing to participate in the Tablet Lending Program * Must have a working email address to participate in teleconferencing (e.g., Zoom calls). Local National Cancer Institute Community Oncology Research Program (NCORP) site staff may assist in setting up a new email address, if needed Exclusion Criteria: * At enrollment, the following diagnosis and/or conditions may not be present (i.e., documented in the medical record or by patient self-report): * Symptomatic claustrophobia * Pregnancy or breast-feeding * Ferromagnetic cerebral aneurysm clips or other intraorbital/intracranial metal; pacemakers, defibrillators, functioning neurostimulator devices or other implanted non-compatible MRI devices, such as tissue expanders * Uncontrolled hypertension (systolic blood pressure \> 190 mm Hg or diastolic blood pressure \> 100 mm Hg) * Inflammatory conditions such as lupus or inflammatory bowel disease, or another medical condition that might compromise safety or successful completion, as determined by the treating physician * Significant ventricular arrhythmias (\> 20 premature ventricular contractions \[PVCs\]/min) * Atrial fibrillation with uncontrolled ventricular response (\> 130 beats per minute \[bpm\]) * Unstable or stable angina (cardiac chest pain) * Severe pulmonary hypertension * Left main coronary artery disease * Symptomatic heart failure * Severe valvular heart disease * Aortic aneurysm (\> 45 mm diameter) or aortic dissection * Uncontrolled slow or fast heart rhythm causing symptoms or hemodynamic compromise * Hypertrophic obstructive cardiomyopathy * Acute myocardial infarction within 28 days of enrollment * Acute pulmonary embolus and/or deep vein thrombosis within 24 weeks prior to enrollment * Plans to relocate within 6 months of enrollment and unable to participate in study procedures * May not be on a simultaneous interventional supportive care (non-therapeutic) clinical trial * May not be undergoing simultaneous treatment for a concurrent second primary cancer (patients with historical cancer will not be excluded if chemotherapy was received ≥ 2 years prior) * May not be currently engaged in ≥ 300 minutes of moderate to vigorous intensity physical activity per week as determined by self-report on the International Physical Activity Questionnaire -Short Form (IPAQ-SF). Site should use the IPAQ-SF screener in the REDCap WF-2401 STEPS-BC screening project to assist in this determination